"... and a weak ASX that lets companies get away with a lack of transparency in reporting their trial results."
The ASX has guidelines for reporting clinical trial results, and MSB consistently ignores them. The most recent example is the CHF results where they have not reported either the primary or secondary endpoint results - but reported on post hoc results that were not listed as either primary or secondary!
I was always worried about covid-ARDS. It was a typical "cheap and dirty" approach based on no pre-clinical data, and built on assumptions it worked in COPD (BTW, it didn't!). My concerns related to the hype around the Mt Sinai results, which were compared not to the experience at Mt Sinai (which presumably would have been good to excellent) but to some undisclosed hospitals which clearly had a poor experience.
But it seems, like a few other biotechs, MSB found it difficult to resist jumping on the covid bandwagon - to the detriment of their shareholders (of which I was one).
The whole sorry saga just highlights a continuing lack of transparency - a trait unfortunately not just confined to MSB in this sector.
MSB Price at posting:
$2.46 Sentiment: Sell Disclosure: Not Held
(20min delay)